MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ajt.14996

Медицинская библиотека · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Manzardo Christian, Londoño Maria C, Castells LLuís, Testillano Milagros, Luis Montero José, Peñafiel Judit, Subirana Marta, Moreno Ana, Aguilera Victoria, Luisa González-Diéguez María, Calvo-Pulido Jorge, Xiol Xavier, Salcedo Magdalena, Cuervas-Mons Valentin, Manuel Sousa José, Suarez Francisco, Serrano Trinidad, Ignacio Herrero Jose, Jiménez Miguel, Fernandez José R, Giménez Carlos, Del Campo Santos, Esteban-Mur Juan I, Crespo Gonzalo, Moreno Asunción, de la Rosa Gloria, Rimola Antoni, Miro Jose M, FIPSE LT-HIV investigators

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.

Для цитирования: Manzardo Christian, Londoño Maria C, Castells LLuís, Testillano Milagros, Luis Montero José, Peñafiel Judit, Subirana Marta, Moreno Ana, Aguilera Victoria, Luisa González-Diéguez María, Calvo-Pulido Jorge, Xiol Xavier, Salcedo Magdalena, Cuervas-Mons Valentin, Manuel Sousa José, Suarez Francisco, Serrano Trinidad, Ignacio Herrero Jose, Jiménez Miguel, Fernandez José R, Giménez Carlos, Del Campo Santos, Esteban-Mur Juan I, Crespo Gonzalo, Moreno Asunción, de la Rosa Gloria, Rimola Antoni, Miro Jose M, FIPSE LT-HIV investigators. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2018. DOI: 10.1111/ajt.14996.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.